These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 24103749

  • 21. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.
    Swick AD, Prabakaran PJ, Miller MC, Javaid AM, Fisher MM, Sampene E, Ong IM, Hu R, Iida M, Nickel KP, Bruce JY, Wheeler DL, Kimple RJ.
    Mol Cancer Ther; 2017 Jul; 16(7):1257-1268. PubMed ID: 28446642
    [Abstract] [Full Text] [Related]

  • 22. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
    Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, Thomas SM, Grandis JR.
    Neoplasia; 2012 Nov; 14(11):1005-14. PubMed ID: 23226094
    [Abstract] [Full Text] [Related]

  • 23. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.
    Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, Martin NM, Ruston L, Pass SL, Pass M.
    Bioorg Med Chem Lett; 2013 Mar 01; 23(5):1212-6. PubMed ID: 23375793
    [Abstract] [Full Text] [Related]

  • 24. AZD8055 Exerts Antitumor Effects on Colon Cancer Cells by Inhibiting mTOR and Cell-cycle Progression.
    Chen Y, Lee CH, Tseng BY, Tsai YH, Tsai HW, Yao CL, Tseng SH.
    Anticancer Res; 2018 Mar 01; 38(3):1445-1454. PubMed ID: 29491070
    [Abstract] [Full Text] [Related]

  • 25. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
    Huo HZ, Zhou ZY, Wang B, Qin J, Liu WY, Gu Y.
    Biochem Biophys Res Commun; 2014 Jan 10; 443(2):406-12. PubMed ID: 24309100
    [Abstract] [Full Text] [Related]

  • 26. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.
    Zheng B, Mao JH, Qian L, Zhu H, Gu DH, Pan XD, Yi F, Ji DM.
    Cancer Lett; 2015 Feb 28; 357(2):468-75. PubMed ID: 25444920
    [Abstract] [Full Text] [Related]

  • 27. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
    Liu M, Gu P, Guo W, Fan X.
    Tumour Biol; 2016 Aug 28; 37(8):11039-48. PubMed ID: 26897748
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of Bcl-2 potentiates AZD-2014-induced anti-head and neck squamous cell carcinoma cell activity.
    Li Y, Cui JT.
    Biochem Biophys Res Commun; 2016 Sep 02; 477(4):607-613. PubMed ID: 27343560
    [Abstract] [Full Text] [Related]

  • 29. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
    Ku BM, Yi SY, Koh J, Bae YH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Oncotarget; 2016 Mar 22; 7(12):14803-13. PubMed ID: 26909611
    [Abstract] [Full Text] [Related]

  • 30. AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma.
    Hu M, Huang H, Zhao R, Li P, Li M, Miao H, Chen N, Chen M.
    Oncol Rep; 2014 Feb 22; 31(2):649-56. PubMed ID: 24297300
    [Abstract] [Full Text] [Related]

  • 31. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM, Pinto N, Khan MI, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Nichols AC.
    Oral Oncol; 2018 Sep 22; 84():95-103. PubMed ID: 30115483
    [Abstract] [Full Text] [Related]

  • 32. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.
    Cancer Res; 2005 Nov 01; 65(21):9953-61. PubMed ID: 16267020
    [Abstract] [Full Text] [Related]

  • 33. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
    Li SH, Lin WC, Huang TL, Chen CH, Chiu TJ, Fang FM, Huang WT, Hsu CM, Luo SD, Lai CC, Su YY, Chuang HC, Chien CY.
    Head Neck; 2016 Apr 01; 38 Suppl 1():E844-52. PubMed ID: 25917382
    [Abstract] [Full Text] [Related]

  • 34. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
    Zhang Y, Jia QA, Kadel D, Zhang XF, Zhang QB.
    Med Sci Monit; 2018 May 03; 24():2735-2743. PubMed ID: 29720580
    [Abstract] [Full Text] [Related]

  • 35. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
    Wei F, Zhang Y, Geng L, Zhang P, Wang G, Liu Y.
    Int J Mol Sci; 2015 Feb 03; 16(2):3267-82. PubMed ID: 25654224
    [Abstract] [Full Text] [Related]

  • 36. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
    Montero JC, Chen X, Ocaña A, Pandiella A.
    Mol Cancer Ther; 2012 Jun 03; 11(6):1342-52. PubMed ID: 22496482
    [Abstract] [Full Text] [Related]

  • 37. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.
    Cirstea D, Santo L, Hideshima T, Eda H, Mishima Y, Nemani N, Mahindra A, Yee A, Gorgun G, Hu Y, Ohguchi H, Suzuki R, Cottini F, Guichard SM, Anderson KC, Raje N.
    Mol Cancer Ther; 2014 Nov 03; 13(11):2489-500. PubMed ID: 25172964
    [Abstract] [Full Text] [Related]

  • 38. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
    Coppock JD, Wieking BG, Molinolo AA, Gutkind JS, Miskimins WK, Lee JH.
    Neoplasia; 2013 Jun 03; 15(6):620-30. PubMed ID: 23730210
    [Abstract] [Full Text] [Related]

  • 39. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 40. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ, Guerra-Librero A, Fernandez-Gil BI, Florido J, García-López S, Martinez-Ruiz L, Mendivil-Perez M, Soto-Mercado V, Acuña-Castroviejo D, Ortega-Arellano H, Carriel V, Diaz-Casado ME, Reiter RJ, Rusanova I, Nieto A, López LC, Escames G.
    J Pineal Res; 2018 Apr 31; 64(3):. PubMed ID: 29247557
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.